Literature DB >> 14750935

Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute.

L Zhang1, H Li, H Zhao, X Zhang, L Ji, R Yang.   

Abstract

With 1.3 billion people, China has the largest population in the world, and therefore has the largest population of persons with haemophilia (PWH). As there is no national registry for haemophilia, it is difficult to ascertain how many PWH have actually been diagnosed. Between January 1983 and June 2002, 1312 patients with coagulation disorders were referred to our hospital, and 1190 patients were evaluable. Among them, 1069 (89.8%) patients had haemophilia, 68 had vWD, 20 had factor XI deficiency, 10 had acquired factor VIII inhibitor and 23 had other coagulation disorders. Of the 1069 PWH, 14.7% were unclassified, 38.4% severe, 35.7% moderate and 11.1% mild. If the unclassified cases were excluded, 45.1% were severe, 41.9% moderate and 13.0% mild. Twenty-nine of the 68 vWD patients had vWF:Ag <5%, and subcategorized as type 3 vWD. Because vWF multimer analysis was not performed in our centre, the remaining vWD patients were not subdivided.

Entities:  

Mesh:

Year:  2003        PMID: 14750935     DOI: 10.1046/j.1351-8216.2003.00826.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  6 in total

1.  Inherited Bleeding Disorders in North Indian Children: 14 years' Experience from a Tertiary Care Center.

Authors:  Tanushree Sahoo; Shano Naseem; Jasmina Ahluwalia; R K Marwaha; Amita Trehan; Deepak Bansal
Journal:  Indian J Hematol Blood Transfus       Date:  2019-11-21       Impact factor: 0.900

2.  Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Authors:  Min Xuan; Feng Xue; Rongfeng Fu; Yanhui Yang; Lei Zhang; Mengsu Tian; Renchi Yang
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

3.  Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial.

Authors:  Runhui Wu; Jing Sun; Weiqun Xu; Qun Hu; Wenqian Li; Jianwen Xiao; Feng'e Yang; Xiaojing Zeng; Yun Zeng; Jianfeng Zhou; Irina Matytsina; Sali Zhang; Michael Pluta; Renchi Yang
Journal:  Ther Clin Risk Manag       Date:  2020-06-23       Impact factor: 2.423

4.  A rare case of acute lymphoblastic leukaemia with hemophilia A.

Authors:  Rahul Sinha; Kirandeep Sodhi; Biju John; Daljit Singh
Journal:  Ital J Pediatr       Date:  2009-12-11       Impact factor: 2.638

5.  [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].

Authors:  W Liu; R F Fu; Y W Zhou; Y Chen; J Yin; Z Q Yu; L H Yang; M F Wang; H Bi; Z P Zhou; X S Zhang; J L Xia; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14

6.  [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.